‘Diversified’ gut-brain axis company Kallyope heading to clinic with $112M series C
Kallyope chooses obesity, IBD for its first two gut-restricted small molecule programs
With what CEO Nancy Thornberry described as a breadth of options spanning multiple therapeutic areas, gut-brain axis company Kallyope will use its new $112 million series C round to bring its first two small molecule programs into the clinic to treat obesity and inflammatory bowel disease.
All of
